The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro

References

• Aguilar-Ponce J, Granados-Garcia M, Villavicencio V, Poitevin-Chacon A, Green D, Duenas-Gonzales A, Herrera-Gomez A, Luna-Ortiz K, Alvarado A, Martinez-Said H, Castillo-Henkel C, Segura-Pacheco B, De la Garza J. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology 2004; 15(2)301–306
   PubMedGoogle Scholar
• Barrueco J R, Jacobson D M, Chang C H, Brockman R W, Sirotnak F M. Proposed mechanism of therapeutic selectivity of 9-ß-D-Arabinofuranosyl-2-fluoroadenine against murine leukaemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumour cells. Cancer Research 1987; 47: 700–706
   PubMed Web of Science ®Google Scholar
• Benasso M, Corvo R, Ponzanelli A, Sanguineti G, Ricci I, Pallestrini E, Santelli A, Vitale V, Rosso R. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous head and neck carcinoma of the head and neck. Annals of Oncology 2004; 15(4)646–652
   PubMedGoogle Scholar
• Brockman R W, Cheng Y C, Schabel F M, Montgomery J A. Metabolism and chemotherapeutic activity of 9-ß-D-arabino-furanosyl-2-Fuoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Research 1980; 40: 3610–3615
   PubMed Web of Science ®Google Scholar
• Boven E, Schippe H, Erkelens C A, Hatty S A, Pinedo H M. The influence of schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. British Journal of Cancer BJC 1993; 68: 52–56
   PubMed Web of Science ®Google Scholar
• Cheson B D, Keating M J, Plunkett W. Nucleoside analogs in cancer therapy. Marcel Dekker, Inc, New York 1997, ISBN 0-8247-9850-3
   Google Scholar
• Chun P Y, Feng F Y, Scheurer A M, Davis M A, Lawrence T S, Nyati M K. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Research 2006; 66(2)981–988
   PubMed Web of Science ®Google Scholar
• Dahlberg W K, Little J B. Differential sensitization of human tumor cells by Ara-A to X-irradiation and its relationship to inherent radioresponse. Radiation Research 1992; 130: 303–308
   PubMedGoogle Scholar
• Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cell neurobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997; 27: 1–20
   PubMedGoogle Scholar
• Elshaikh M, Hunter N, Milas L, Hittelman W N, Ang K K, Mason K. Time dependent modulation of jejunal radioresponse with gemcitabine. Proceedings of the 45th Annual Meeting of radiation Research Society. ChicagoUSA 1997; A528
   Google Scholar
• Facchinetti A, Tessarollo L, Mazzocchi M, Kingston R, Collavo D, Biasi G. An improved method for detection of DNA fragmentation. Journal of Immunological Methods 1991; 136: 125–131
   PubMed Web of Science ®Google Scholar
• Fertil B, Dertinger H, Courdi A, Malaise E P. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiation Research 1984; 99: 73–84
   PubMed Web of Science ®Google Scholar
• Fujii T, Hunter N, Elshaikh M, Hittelmann W N, Plunkett W, Ang K K, Milas L. Gemcitabine improves the therapeutic ratio of radiotherapy in mouse tumours after single dose irradiation. Proceedings of the 45th Annual Meeting of the Radiation Research Society. ChicagoUSA 1997; A529
   Google Scholar
• Grégoire V, Hunter N, Brock W, Milas L, Plunkett W, Hittelman W N. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single dose irradiation. International Journal of Radiation Oncology Biology Physics 1994a; 30: 363–371
   PubMedGoogle Scholar
• Grégoire V, Hunter N, Milas L, Brock W A, Plunkett W, Hittelman W N. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Research 1994b; 54: 468–474
   PubMed Web of Science ®Google Scholar
• Grégoire V, Van N T, Stephens C. The role of fludarabine-induced apoptosis and cell cycle synchronisation in enhanced murine tumor radiation response in vivo. Cancer Research 1994c; 54(23)6201–6209
   PubMedGoogle Scholar
• Grégoire V, Ruifrok A C, Price R E, Brock W A, Hittelmann W N, Plunkett W K, Ang K K. Effect of intra-peritoneal Fludarabine on rat spinal cord tolerance to fractionated irradiation. Radiotherapy and Oncology 1995; 36: 50–55
   PubMedGoogle Scholar
• Grégoire V, Hittelmann W N. Nucleoside analogs as radiosensitizing agents. Nucleoside analogues in Cancer therapy, B D Cheson, M J Keating, W Plunkett. Marcel Dekker, New York 1997; 315–358
   Google Scholar
• Grégoire V, Debast M, Rosier J F, Beauduin M, Bruniaux M, Decoster B, Scalliet P. Relationship between deoxycytidine kinase (cdk) activity and dck over deoxycytidine deaminase activity ratio, and radiosensitization by fludarabine and gemcitabine. Proceedings of American association for Cancer Research 39. 1998a; A2597
   Google Scholar
• Grégoire V, Beauduin M, Bruniaux M, De Coster B, Octave Prignot M, Scalliet P. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction of a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. International Journal of Radiation Biology 1998b; 73: 511–520
   PubMedGoogle Scholar
• Grégoire V, Hittelmann W N, Rosier J F, Milas L. Chemo-radiotherapy: Radiosensitizing nucleoside analogues (Review). Oncology Reports 1999; 6: 949–957
   PubMedGoogle Scholar
• Grégoire V, Ang K K, Rosier J F, Beaudin M, Garden A S, Hamoir M, Hittelmann W N, Humblet Y, Khuri F R, Milas L, Mitine C, Scalliet P. A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamos cell carcinoma. Radiotherapy and Oncology 2002; 63(2)187–193
   PubMedGoogle Scholar
• Heinemann V, Schulz L, Issels R D, Plunkett W. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Seminars in Oncology 1995; 22: 11–18
   PubMed Web of Science ®Google Scholar
• Hertel L, Boder G B, Kroin J S, Rinzel S M, Poore G A, Todd G C, Grindey G B. Evaluation of the antitumor activity of gemcitabine (2′2′-difluoro-2′deoxycitidine). Cancer Research 1990; 50: 4417–4422
   PubMed Web of Science ®Google Scholar
• Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-ß-D-arabinofuranosyl-2-Fluoroadenine: A mechanism for cytotoxicity. Journal of Biological Chemistry 1990; 265: 16617–16625
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Huang P, Keating M J, Plunkett W. Differential incorporation of ara-c, gemcitabine, andfludarabine into replicating and repairing DNA in proliferating human leukaemia cells. Blood 1997; 90: 270–278
   PubMed Web of Science ®Google Scholar
• Jayanth R V, Hittelman W N. 9-ß-D-arabinofuranosyl-2-Fluoroadenine inhibits both the slow and fast components of chromosome repair (abstract). Radiation research: A 20th century perspective, J D Chapman, W C Dewey, G F Whitemore. Academic Press, San Diego, CA 1991; 411
   Google Scholar
• Johnson S, Smith A G, Löffler H, Ösby E, Juliusson G, Emmerich B, Wyld P, Hiddemann W, The French Cooperative Group. Multicentre prospektive randomised trial of fludarabine versus cyclophosphamid, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438
   PubMed Web of Science ®Google Scholar
• Joschko M A, Webster L K, Groves J, Yuen K, Palatsides M, Ball D L, Millward M J. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiation Oncology Investigations 1997; 5: 62–71
   PubMedGoogle Scholar
• Keating M J, Kantarjian H, Talpaz M, Redmann J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich E J, McCredie K B. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Kim J H, Alfieri A, Kim S H, Fuks Z. The potentiation of radiation response on murine tumor by Fludarabine phosphate. Cancer Letters 1986; 31: 69–76
   PubMedGoogle Scholar
• Lathan B, Diehl V, Clark G M, von Hoff D D. Cytotoxic activity of 9-ß-D-arabinofuranosyl-2-Fluoroadenine-5-monophosphate (Fludarabine) in a human tumor cloning system. European Journal of Cancer and Clinical Oncology 1988; 24: 1891–1895
   PubMedGoogle Scholar
• Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber K J. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′deoxycitidine) within the cell cycle in vitro. International Journal of Radiation Oncology Biology Physics 1998; 41: 875–882
   PubMed Web of Science ®Google Scholar
• Laurent D, Pradier O, Schmidberger H, Rave-Fränk M, Frankenberg D, Hess C F. Radiation rendered more cytotoxic by Fludarabine monophosphate in a human oropharynx carcinoma cell-line than in fetal lung Fibroblasts. Journal of Cancer Research and Clinical Oncology 1998; 124: 485–492
   PubMedGoogle Scholar
• Lawrence T S, Chang E, Hahn T M, Hertel L W, Shewach D S. Radiosensitization of pancreatic cancer cells by 2′-2′ difluoro-2′ deoxycytidine. International Journal of Radiation Oncology Biology Physics 1996; 41: 867–872
   Google Scholar
• Lawrence T S, Chang E, Hahn T M, Shewach D S. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′-2′ deoxycyitidine (Gemcitabine). Clinical Cancer Research 1997; 3: 777–782
   PubMed Web of Science ®Google Scholar
• Mackey J R, Mani R S, Selner M, Mowles D, Young J D, Belt J A, Crawford C R, Cass C E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Research 1998; 58: 4349–4357
   PubMed Web of Science ®Google Scholar
• Malaise E P, Debieu D, Chavaudra N, Grinfeld S. The effect of the oxic cell sensitizer b-Ara-A on human fibroblasts in plateau and in exponential growth phases. International Journal of Radiation Oncology Biology Physics 1989; 16: 1257–1259
   PubMed Web of Science ®Google Scholar
• Milas L, Fuji T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang K K, Hittelman W. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Research 1999; 59: 107–114
   PubMed Web of Science ®Google Scholar
• Milano M T, Haraf D J, Stenson K M, Witt M E, Eng C, Mittal B B, Argiris A, Pelzer H, Kozloff M F, Vokes E E. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor prognosis cancer of the head and neck. Clinical Cancer Research 2004; 10(15)4922–4932
   PubMedGoogle Scholar
• Milano M T, Vokes E E, Salama J K, Stenson K M, Kao J, Witt M E, Mittal B B, Argiris A, Weichselbaum R R, Haraf D J. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. International Journal of Radiation Oncology Biology Physics 2005; 61(4)1095–1106
   Google Scholar
• Mittelmann A, Ashikari R, Ahmed T, Savona S, Arnold P, Arlin Z. Phase II trial of fludarabine phosphate (f-ara-AMP) in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology 1988; 22: 63–64
   PubMedGoogle Scholar
• Mose S, Class R, Weber H W, Oszwald A, Rahn A, Brady L W, Böttcher H D. Komnination von Radiotherapie und Gemcitabine. Strahlentherapie und Onkologie 2001; 178: 59–70
   Google Scholar
• Mose S, Karapetian M, Jüling-Pohlit L, Taborski B, Ramm U, Damrau M, Rahn A, Böttcher H D. The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine. Strahlentherapie Onkologie 1999; 175: 78–83
   PubMedGoogle Scholar
• Mose S, Karapetian M, Jüling-Pohlit L, Taborski B, Damrau M, Ramm U, Rahn A, Böttcher H D. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Research 2000; 20: 401–405
   PubMed Web of Science ®Google Scholar
• Mullen J, Xu Y Z, Lepek K, Plunkett W, Rich T. Cytotoxicity and radiosensitization by gemcitabine in exponential human colon adenocarcinoma cells. Proceedings of the 42nd Annual meeting of the radiation Research Society. Nashville, TEUSA 1994; A 206
   Google Scholar
• Pauwels B, Korst A EC, Lardon F, Vermorken J B. Combined modality therapy of gemcitabine and radiation. Oncologist 2005; 10(1)34–51
   PubMed Web of Science ®Google Scholar
• Pauwels B, Korst A EC, Lambrechts H AJ, Pattyn G GO, Lardon F, Vermorken J B. The radiosensitizing effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemotherapy and Pharmacology 2006; 58: 219–228
   PubMedGoogle Scholar
• Plunkett W, Ghandi V, Chubb S, Nowak B, Heinemann V, Mineishi S, Sen A, Hertel L W, Grindey G B. 2′,2′-difluoro-deoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides Nucleic Acids 1989; 8: 775–785
   Google Scholar
• Plunkett W, Huang P, Ghandi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6: 7–13
   PubMed Web of Science ®Google Scholar
• Plunkett W, Chubb S, Alexander L, Montgomery J. Comparison of the toxicity and metabolism of 9-ß-D-arab-inofuranosyl-2-Fluoroadenine and 9-ß-D-arabinofuransyladenine in human lymphoblastoid cells. Cancer Research 1980; 40: 2349–2355
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Ghandi V. Metabolism and action of Fludarabine phosphate. Seminars in Oncology 1990, Suppl. 8: 3–17
   PubMedGoogle Scholar
• Plunkett W, Ghandi V, Huang P, Robertson L E, Yang L Y, Grégoire V, Estey E, Keating M J. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Seminars in Oncology 1993; 20(Suppl. 7)2–12
   PubMedGoogle Scholar
• Rave-Fränk M, Virsik-Peuckert P, Bertram K, Schmidberger H. Chromosome analysis in X-irradiated primary cells of a human squamous cell carcinoma by fluorescence in situ hybridization. International Journal of Radiation Biology 1996; 69: 695–700
   PubMed Web of Science ®Google Scholar
• Rockwell S, Grindey G B. Effect of 2′-2′difluorodeoxycitidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncology Research 1992; 4: 151–155
   PubMedGoogle Scholar
• Rosier J F, Michaux L, Ameye G, Cedervall B, Libouton J M, Octave-Prignot M, Verellen-Dumoulin C, Scalliet P, Grégoire V. The radioenhancement of two human head and neck squamous cell carcinomas by 2′-2′ difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs. Mutation Research 2003; 19(1–2)15–26
   Google Scholar
• Ruiz van Haperen V WT, Veerman G, Boven E, Noorhuis P, Vermoken J B, Peters G J. Schedule dependence of sensitivity to 2′2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tulour cell lines and solid tumours. Biochemical Pharmacology 1994; 48: 1327–1339
   PubMed Web of Science ®Google Scholar
• Scalliet P, Goor C, Galdermans D, van Meebeek J, Groen H JM, van der Leest A HD, Westerink H, Jungnelius U, Turrisi A. Gemzar (Gemzitabine) with thoracic radiotherapy – a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proceedings of The American Society of Clinical Oncology (ASCO) 1998; 17: A1923
   Google Scholar
• Shewach D A, Hahn T M, Chang E, Hertel H W, Lawrence T S. Metabolism of 2′-2′ difluoro-2′deoxycitidine and radiation sensitization of human colon carcinoma cells. Cancer Research 1994; 54: 3218–3223
   PubMed Web of Science ®Google Scholar
• Shewach D S, Lawrence T S. Radiosensitization of human tumor cells by gemcitabine in vitro. Seminars in Oncology 1995; 22: 68–71
   PubMed Web of Science ®Google Scholar
• Spriggs D, Robbins G, Mitchell T, Kufe D. Incorporation of 9-ß-D-arabinofuranosyl-2-Fluoroadenine into HL-60 cellular RNA and DNA. Biochemical Pharmacology 1986; 35: 247–252
   PubMed Web of Science ®Google Scholar
• Spector D L, Goldman R D, Leinwand L A. Culture and biochemical analysis of cells. Cell: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1998; 1: 156
   Google Scholar
• Steel G G. Terminology in the description of drug-radiation interactions. International Journal of Radiation Oncology Biology Physics 1979; 5: 1145–1150
   PubMed Web of Science ®Google Scholar
• Toschi L, Finocchiaro G, Bartolini S, Gioia V, Capuzzo F. Role of gemcitabine in cancer therapy. Future Oncology 2005; 1(1)7–17
   PubMedGoogle Scholar
• Weiss G B, Metch B, von Hof D D, Taylor S A, Saiers J H. Phase II trial of fludarabine phosophate in patients with head and neck cancer. A southwest oncology group study. Cancer Treatment Report 1987; 71: 1313–1314
   PubMedGoogle Scholar